866-997-4948(US-Canada Toll Free)

Global Glaucoma Therapeutics Market 2017-2021

Published By :

Technavio

Published Date : Oct 2017

Category :

Infectious Disease

No. of Pages : 97 Pages

About Glaucoma Therapeutics

Glaucoma is an ophthalmic disorder that damages the optic nerves in the eyes. The disease is associated with elevated IOP and over time leads to the damage of the optic nerves, by destroying their cell bodies and delicate fibers. This can lead to partial loss of vision or complete blindness. Increased IOP is majorly due to the build-up of aqueous humor, which circulates in the front of an eye.

Technavios analysts forecast the global glaucoma therapeutics market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global glaucoma therapeutics market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Glaucoma Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Allergan
Pfizer
Novartis
Merck
Other prominent vendors
Bayer HealthCare
Akorn
Bausch & Lomb
Santen Pharmaceutical
Teva Pharmaceutical
VISTAKON
Market driver
Increasing geriatric population leading to higher prevalence rate of glaucoma
For a full, detailed list, view our report

Market challenge
Growing popularity of alternative treatment options
For a full, detailed list, view our report

Market trend
Rising investment in R&D activities
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: RESEARCH METHODOLOGY
PART 03: INTRODUCTION
Market outline
PART 04: MARKET LANDSCAPE
Market overview
Five forces analysis
PART 05: PIPELINE LANDSCAPE
PART 06: MARKET SEGMENTATION BY DRUG CLASS
Global glaucoma therapeutics market by prostaglandin analogs
Global glaucoma therapeutics market by beta blockers
Global glaucoma therapeutics market by alpha agonists
Global glaucoma therapeutics market by carbonic anhydrase inhibitors
Global glaucoma therapeutics market by others
PART 07: REGIONAL LANDSCAPE
Geographical segmentation
Regional comparison
Americas market size and forecast
EMEA market size and forecast
APAC market size and forecast
Market opportunity
PART 08: DECISION FRAMEWORK
PART 09: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
Competitive scenario
PART 12: KEY VENDOR ANALYSIS
Allergan
Pfizer
Novartis
Merck
Other prominent vendors
PART 13: APPENDIX
List of abbreviations
List of Exhibits
Exhibit 01: Global ophthalmic disorder treatment market
Exhibit 02: Types of glaucoma
Exhibit 03: Factors leading to angle-closure glaucoma
Exhibit 04: Types of secondary glaucoma
Exhibit 05: Global glaucoma therapeutics market snapshot
Exhibit 06: Global glaucoma therapeutics market 2016-2021 ($ millions)
Exhibit 07: Five forces analysis
Exhibit 08: Major pipeline molecules by vendors
Exhibit 09: Key clinical trials
Exhibit 10: Global glaucoma therapeutics market by drug class ($ millions)
Exhibit 11: Global glaucoma therapeutics market by drug class 2016-2021
Exhibit 12: Global glaucoma therapeutics market by prostaglandin analogs 2016-2021 ($ millions)
Exhibit 13: Advantages and disadvantages of prostaglandin analogs present in global glaucoma therapeutics market
Exhibit 14: Global glaucoma therapeutics market by beta blockers 2016-2021 ($ millions)
Exhibit 15: Common beta blockers used as glaucoma therapeutics
Exhibit 16: Global glaucoma therapeutics market by alpha agonists 2016-2021 ($ millions)
Exhibit 17: Common alpha agonists used for glaucoma treatment
Exhibit 18: Global glaucoma therapeutics market by carbonic anhydrase inhibitors 2016-2021 ($ millions)
Exhibit 19: Common carbonic anhydrase inhibitors used for glaucoma treatment
Exhibit 20: Global glaucoma therapeutics market by others 2016-2021 ($ millions)
Exhibit 21: Cholinergic agents used for glaucoma treatment
Exhibit 22: Americas market size and forecast
Exhibit 23: Regional comparison
Exhibit 24: Americas market size and forecast
Exhibit 25: Americas Year over year growth
Exhibit 26: A snapshot on eye diseases in US 2014 and 2030
Exhibit 27: Snapshot of economic and healthcare expenditure of US 2014-2015
Exhibit 28: Economic and healthcare snapshot of Canada
Exhibit 29: Top three countries in Americas
Exhibit 30: Economic and healthcare snapshot of Europe 2014
EMEA market size and forecast
Exhibit 31: EMEA year-over-year growth
Exhibit 32: Medication scenario for glaucoma in Europe
Exhibit 33: Top three countries in EMEA
Exhibit 34: APAC market size and forecast
Exhibit 35: APAC year-over-year growth
Exhibit 36: Top three countries in APAC
Exhibit 37: World population by age group 2015 and 2050
Exhibit 38: Percentage of population aged 60 and above by region 2015 and 2050
Exhibit 39: Non-therapeutic glaucoma treatment
Exhibit 40: Side effects of the commonly used glaucoma medications
Exhibit 41: Need of new drug delivery systems
Exhibit 42: Novel efforts in glaucoma therapeutics market
Exhibit 43: Competitive structure analysis of global glaucoma therapeutics market 2016
Exhibit 44: Allergan: Key highlights
Exhibit 45: Allergan: Strength assessment
Exhibit 46: Allergan: Strategy assessment
Exhibit 47: Allergan: Opportunity assessment
Exhibit 48: Pfizer: Key highlights
Exhibit 49: Pfizer: Strength assessment
Exhibit 50: Pfizer: Strategy assessment
Exhibit 51: Pfizer: Opportunity assessment
Exhibit 52: Novartis: Key highlights
Exhibit 53: Novartis: Strength assessment
Exhibit 54: Novartis: Strategy assessment
Exhibit 55: Novartis: Opportunity assessment
Exhibit 56: Merck: Key highlights
Exhibit 57: Merck: Strength assessment
Exhibit 58: Merck: Strategy assessment
Exhibit 59: Merck: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *